Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897832 · ClinicalTrials.gov registry record
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 50
- Enrollment target
NCT00897832 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT00897832 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in predicting response to treatment in patients who have undergone surgery for pancreatic cancer.
Interventions
- OTHER laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897832
The ClinicalTrials.gov registry entry for NCT00897832 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00897832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897832 about?
NCT00897832 is a clinical study titled "Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer". RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is l...
What is the current status of trial NCT00897832?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2007-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00897832?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00897832?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.